Non-invasive ventilation touted for COPD treatment at respiratory meeting
ResMed has presented results at the European Respiratory Society international congress, touting home non-invasive ventilation (NIV) as part of a treatment regime that can positively impact current practice and improve the lives of patients with COPD.
COPD, or chronic obstructive pulmonary disease, affects around three million people in the UK. It is a condition where the airways become inflamed and the air sacs in the lung become damaged. This can cause the narrowing of airways, which can make breathing more difficult. It can therefore greatly affect quality of life.
Portable oxygen therapy, remote monitoring technology and home non-invasive ventilation now all form part of the company’s offering in this area. In the home oxygen therapy-home mechanical ventilation study, it was observed that the addition of home non-invasive ventilation improves admission-free survival in hypercapnic COPD patients, or those with high levels of carbon dioxide in the blood, following a life-threatening exacerbation of COPD.
Patients’ median hospital admission-free survival increased from 1.4 months to 4.3 months in the group receiving non-invasive ventilation in the study.
As well as providing a series of at-home COPD management products, ResMed provide a cloud-based patient management system which ensures healthcare professionals can remotely identify patients in need of attention, and make timely interventions.
Holger Woehrle, VP of clinical research at ResMed, says: “These results build on and add further weight to existing evidence supporting the broader use of home NIV in patients living with COPD, whilst also underlining the accepted benefits of home NIV in terms of reducing hospital admissions and improving patient outcomes. We hope these results will have a positive impact on current practice and encourage more healthcare professionals to consider the role of home NIV in managing their COPD patients.”
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to …
The European Medicines Agency (EMA) has announced the approval of AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium …